Pancreatic cancer is the third leading cause of cancer death in the U.S., effecting more than 337,000 people globally each year. Yet only 7% of diagnosed patients survive beyond 5 years. Most current cancer therapies (including chemotherapy, radiation or surgery) are associated with significant side effects that further reduce the patient’s quality of life. It's time for some disruptive innovation to meet this urgent unmet medical need.
Sun BioPharma Inc. is a next-generation biopharmaceutical company developing disruptive therapeutics for diseases of the pancreas, including pancreatic cancer and pancreatitis. The company has scientific collaborations with pancreatic disease experts at Honor Health in Scottsdale, AZ, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, Mayo Clinic Scottsdale, the Austin Health Cancer Trials Centre and the Ashford Cancer Centre in Adelaide, Australia.

Sun BioPharma has selected Mindsailing as its partner to develop branding and sales materials and advance their marketing communications. Over the coming months, we’ll endeavor to help Sun BioPharma create communications strategies that can advance innovations in cancer treatments.
Mindsailing is an innovation agency. We help brands sail industry and cultural sea change with business strategies, marketing communications and innovation workshops. We believe great brands are in the business of good.